Clinical Trials

Multiple Myeloma

NCT04504825 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

125 enrolled

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT04512235 2026-03-17

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

281 enrolled

Phase 2 Not yet recruiting

Immunoglobulin Light-chain Amyloidosis, Paraproteinemias

NCT07224672 2026-03-17

ALANIS

60 enrolled

Immunoglobulin Light-chain Amyloidosis, Amyloidosis

NCT04181827 2026-03-16

CARTITUDE-4

419 enrolled 10 charts

Phase 1 Active not recruiting

Multiple Myeloma

NCT04722146 2026-03-13

MajesTEC-2

140 enrolled

Multiple Myeloma

NCT04923893 2026-03-13

CARTITUDE-5

743 enrolled

Multiple Myeloma

NCT06158841 2026-03-13

CERVINO

380 enrolled

Multiple Myeloma

NCT06208150 2026-03-13

MonumenTAL-6

795 enrolled

Phase 2 Active not recruiting

Multiple Myeloma

NCT06577025 2026-03-13

aMMbition

43 enrolled

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

508 enrolled

Multiple Myeloma

NCT05519085 2026-03-11

SUCCESSOR-1

810 enrolled

Phase 1 Active not recruiting

Multiple Myeloma, Recurrence

NCT03984097 2026-03-10

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

50 enrolled

Phase 2/3 Not yet recruiting

Multiple Myeloma, Neoplasms, Plasma Cell

NCT07428369 2026-02-23

LINKER-MM8

1,570 enrolled

Multiple Myeloma

NCT05572515 2026-02-13

MajesTEC-9

614 enrolled

Multiple Myeloma, Recurrence

NCT06152575 2026-02-03

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

492 enrolled

Multiple Myeloma, Neoplasms, Plasma Cell

NCT04414475 2026-02-02

A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Phase 2 Recruiting

127 enrolled

Multiple Myeloma

NCT05556616 2026-01-29

iinnovate-2

Phase 1 Terminated

15 enrolled 15 charts

Multiple Myeloma

NCT07297329 2026-01-29

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

292 enrolled

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

317 enrolled

Multiple Myeloma

NCT03652064 2026-01-20

A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

395 enrolled 1 FDA

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

300 enrolled